In Israel, the BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 was approved for use in adolescents in June 2021, shortly before an outbreak of B.1.617.2 (Delta) variant-dominant infection. We evaluated short-term vaccine effectiveness and found the vaccine to be highly effective among this population in this setting.
Keywords: 2019 novel coronavirus disease; COVID-19; Delta variant; Israel; SARS-CoV-2; adolescents; coronavirus disease; respiratory infections; severe acute respiratory syndrome coronavirus 2; vaccine effectiveness; viruses; zoonoses.